Robeco Institutional Asset Management
CPRX

Robeco Institutional Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Robeco Institutional Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-66,304
Closed -$1.1M – 1059
2023
Q1 		$1.1M Buy
66,304
+11,365
+21% +$187K ﹤0.01% 763
2022
Q4 		$1.02M Hold
54,939
– – ﹤0.01% 776
2022
Q3 		$704K Buy
+54,939
New +$651K ﹤0.01% 733

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Robeco Institutional Asset Management's CPRX Position: Q2 2023 in Review

Robeco Institutional Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2023, closing a stake of 66,304 shares — an estimated $1.1M sold.

Robeco Institutional Asset Management first reported a position in CPRX in Q3 2022 and held it in 3 quarters. The position peaked at $1.1M in Q1 2023. 248 funds tracked by Wall St. Rank hold CPRX as of Q2 2023.

  • Robeco Institutional Asset Management reported no remaining Catalyst Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Robeco Institutional Asset Management sold 66,304 Catalyst Pharmaceutical shares in Q2 2023, an estimated $1.1M.
  • Robeco Institutional Asset Management first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 3 quarters.
  • Robeco Institutional Asset Management's Catalyst Pharmaceutical position peaked at $1.1M in Q1 2023.
  • 248 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2023.

Based on Robeco Institutional Asset Management's 13F filing for Q2 2023, filed 24 Jul 2023.